Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» CHRS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

CHRS Guru Trades in Q1 2016

Steven Cohen 131,200 sh (New)
George Soros Sold Out
» More
Q2 2016

CHRS Guru Trades in Q2 2016

Paul Tudor Jones 11,300 sh (New)
Jim Simons 94,500 sh (New)
Steven Cohen 37,500 sh (-71.42%)
» More
Q3 2016

CHRS Guru Trades in Q3 2016

Joel Greenblatt 17,363 sh (New)
Steven Cohen Sold Out
Jim Simons Sold Out
Paul Tudor Jones 10,670 sh (-5.58%)
» More
Q4 2016

CHRS Guru Trades in Q4 2016

Steven Cohen 601,034 sh (New)
Joel Greenblatt 32,982 sh (+89.96%)
Paul Tudor Jones 14,396 sh (+34.92%)
» More
» Details

Insider Trades

Latest Guru Trades with CHRS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 541711    SIC: 2836
Compare:OTCPK:PFSCF, NAS:LOXO, NAS:XNCR, NAS:RGEN, NAS:ACOR, NAS:ALDR, NAS:BPMC, NAS:XLRN, NAS:GBT, OTCPK:BVNRY, NYSE:AXON, NAS:DERM, NYSE:EBS, NAS:INSM, NAS:EDIT, NAS:AMRN, NAS:CORT, NAS:ZIOP, NAS:CLCD, NAS:FOLD » details
Coherus BioSciences Inc is a late-stage clinical biologics platform company. The Company is engaged in developing biosimilar therapeutics.

Top Ranked Articles about Coherus BioSciences Inc

Coherus Biosciences' Humira Petition Denied AbbVie’s Humira patent remains untouched
AbbVie’s (NYSE:ABBV) shareholders received positive news from the Patent Trial and Appeal Board of the U.S. Patent and Trademark Office in regard to the legitimacy of AbbVie’s Humira formulation patent. Read more...

Ratios

vs
industry
vs
history

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history

More Statistics

Revenue (TTM) (Mil) $199.5
EPS (TTM) $ -3.05
Short Percentage of Float18.31%
52-Week Range $13.10 - 31.98
Shares Outstanding (Mil)48.81
» More Articles for CHRS

Headlines

Articles On GuruFocus.com
Coherus Biosciences' Humira Petition Denied Nov 08 2016 
A Look at Pharma Company Dermira's Performance Mar 27 2015 

More From Other Websites
Coherus BioSciences to Report Fourth Quarter and Full Year 2016 Financial Results on March 13th Feb 21 2017
Coherus BioSciences Announces New Employment Inducement Grants Feb 17 2017
COHERUS BIOSCIENCES, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other... Feb 13 2017
Coherus Biosciences Inc (CHRS) Could Be A Discount Entry On The Pullback Feb 08 2017
Coherus Prices Public Offering of Common Stock Feb 08 2017
Coherus Announces Proposed Public Offering of Common Stock Feb 07 2017
COHERUS BIOSCIENCES, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jan 31 2017
Coherus BioSciences Files Four Petitions for Inter Partes Review Against AbbVie’s HUMIRA®... Jan 31 2017
Coherus BioSciences, Inc. – Value Analysis (NASDAQ:CHRS) : January 27, 2017 Jan 27 2017
Coherus BioSciences, Inc. breached its 50 day moving average in a Bullish Manner : CHRS-US : January... Jan 26 2017
ETFs with exposure to Coherus BioSciences, Inc. : January 19, 2017 Jan 19 2017
Coherus Offers Positive Phase III Data on Humira Biosimilar Jan 13 2017
Coherus BioSciences Announces Positive Topline 24-Week Treatment Phase Three Results for CHS-1420... Jan 10 2017
Coherus BioSciences, Inc. breached its 50 day moving average in a Bearish Manner : CHRS-US : January... Jan 10 2017
Coherus BioSciences Management to Present at The 35th Annual J.P. Morgan Healthcare Conference Jan 04 2017
Coherus BioSciences, Inc. breached its 50 day moving average in a Bullish Manner : CHRS-US :... Dec 19 2016
Coherus BioSciences to Present at BMO – Prescriptions for Success Healthcare Conference on... Dec 07 2016
Coherus BioSciences, Inc. – Value Analysis (NASDAQ:CHRS) : December 7, 2016 Dec 07 2016
Coherus BioSciences, Inc. breached its 50 day moving average in a Bullish Manner : CHRS-US :... Dec 06 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)